April 2 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N :
* TALTZ® (IXEKIZUMAB) APPROVED BY HEALTH CANADA FOR THE TREATMENT OF PEDIATRIC PATIENTS (SIX TO LESS THAN 18 YEARS OF AGE) WITH MODERATE- TO SEVERE PLAQUE PSORIASIS
April 2 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N :
* TALTZ® (IXEKIZUMAB) APPROVED BY HEALTH CANADA FOR THE TREATMENT OF PEDIATRIC PATIENTS (SIX TO LESS THAN 18 YEARS OF AGE) WITH MODERATE- TO SEVERE PLAQUE PSORIASIS